|
Volumn 20, Issue 1, 1999, Pages 16-39
|
Carvedilol and the Food and Drug Administration (FDA) approval process: The FDA paradigm and reflections on hypothesis testing
|
Author keywords
Advisory committee; Alpha blocker; Beta blocker; Carvedilol; Congestive heart failure; FDA; FDA paradigm; strength of evidence; Type I error
|
Indexed keywords
CARVEDILOL;
NEW DRUG;
BIOSTATISTICS;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
DATA ANALYSIS;
DECISION MAKING;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MORBIDITY;
MORTALITY;
SHORT SURVEY;
|
EID: 0032971979
PISSN: 01972456
EISSN: None
Source Type: Journal
DOI: 10.1016/S0197-2456(98)00054-3 Document Type: Article |
Times cited : (66)
|
References (9)
|